Logo
x

Search

Subscribe Now

novartis

Novartis’ Vanrafia (Atrasentan) Receives the US FDA’s Accelerated Approval for Primary IgA Nephropathy (IgAN)

Novartis’ Vanrafia (Atrasentan) Receives the US FDA’s Accelerated Approval for Primary IgA Nephropathy (IgAN)

  • April 3, 2025
Novartis Reports the US FDA’s Approval of Fabhalta (Iptacopan) to Treat C3 glomerulopathy

Novartis Reports the US FDA’s Approval of Fabhalta (Iptacopan) to Treat C3 glomerulopathy

  • March 21, 2025
Novartis Reports P-III (STEER & STRENGTH) trials data of OAV101 IT for Spinal Muscular Atrophy

Novartis Reports P-III (STEER & STRENGTH) trials data of OAV101 IT for Spinal Muscular Atrophy

  • March 20, 2025
Novartis to Acquire Anthos Therapeutics for ~$3.1B

Novartis to Acquire Anthos Therapeutics for ~$3.1B

  • February 11, 2025
Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular Atrophy (SMA)

Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular...

  • December 30, 2024
Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

  • December 11, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.